Compare Kinder Morgan Inc (KMI) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kinder Morgan Inc vs Natera Inc. Common Stock — how do they compare? Kinder Morgan Inc trades at $33.53 (market cap $74.26B), while Natera Inc. Common Stock trades at $393.93 (market cap $57.03B). The key difference: Kinder Morgan Inc is the larger of the two by market cap, and Kinder Morgan Inc pays a 3.54% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Kinder Morgan Inc for 151 Days and Natera Inc. Common Stock for 0 Days on average.
| KMI | NTRA | |
|---|---|---|
Market Cap | $74.26B | $57.03B |
Volume | 12,072,157 | 1,131,157 |
Sector | Energy | Health |
52-Week High | $34.31 | $425.64 |
52-Week Low | $25.84 | $179.42 |
Typical Hold Time | 151 Days | 0 Days |
Enterprise Value | $106.31B | $56.18B |
Dividend Yield | 3.54% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kinder Morgan (KMI) trades at $33.43, up 1.06% with a bullish technical signal and strong earnings momentum after beating estimates for three consecutive quarters. The company maintains solid fundamentals with $16.94B revenue, 19.31% net margin, and a $6B-$7B growth pipeline. Analyst consensus is mixed with 47% buy ratings and a $37.20 price target, while technical indicators show support at $33 and resistance at $34.
KMI offers income investors a compelling dividend yield with growth potential from natural gas infrastructure demand, though elevated debt levels and energy market volatility present risks. The stock's current valuation at 21.57 P/E appears reasonable given earnings growth trajectory and stable fee-based revenue model.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Kinder Morgan Inc
Kinder Morgan is one of the largest midstream energy firms in North America, with an interest in or an operator on about 83,000 miles in pipelines and over 140 storage terminals. The company is active in the transportation, storage, and processing of natural gas, crude oil, refined products, natural gas liquids, and carbon dioxide. The majority of Kinder Morgan's cash flows stem from fee-based contracts for handling, moving, and storing fossil fuel products.
Read more on KMI →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
